TrueBlue (TBI) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrueBlue in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TBI shares.
View TBI analyst ratings or view top-rated stocks.

1 analysts have issued 1-year target prices for TrueBlue's stock. Their TBI share price forecasts range from $18.00 to $20.00. On average, they predict the company's share price to reach $19.00 in the next year. This suggests a possible upside of 29.5% from the stock's current price.
View analysts price targets for TBI or view top-rated stocks among Wall Street analysts.

TrueBlue's stock was trading at $19.58 at the start of the year. Since then, TBI stock has decreased by 25.1% and is now trading at $14.67.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, October 23rd 2023.
View our TBI earnings forecast.

TrueBlue, Inc. (NYSE:TBI) announced its earnings results on Monday, July, 24th. The business services provider reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.06. The business services provider had revenue of $475.59 million for the quarter, compared to analyst estimates of $496.11 million. TrueBlue had a net margin of 0.78% and a trailing twelve-month return on equity of 8.88%. The company's revenue for the quarter was down 16.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.82 EPS.

First Trust Dow Jones Select Microcap Index Fund holds 83,212 shares of TBI stock, representing 0.79% of its portfolio.

TrueBlue updated its third quarter 2023 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $483.61 million-$506.63 million, compared to the consensus revenue estimate of $516.88 million.

34 employees have rated TrueBlue Chief Executive Officer Patrick Beharelle on Glassdoor.com. Patrick Beharelle has an approval rating of 56% among the company's employees. This puts Patrick Beharelle in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other TrueBlue investors own include International Business Machines (IBM), Intel (INTC), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), The Goldman Sachs Group (GS), AT&T (T), Zynga (ZNGA), AbbVie (ABBV) and Amgen (AMGN).

TrueBlue trades on the New York Stock Exchange (NYSE) under the ticker symbol "TBI."

Shares of TBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TBI stock can currently be purchased for approximately $14.67.

TrueBlue (NYSE:TBI) has a market capitalization of $454.77 million and generates $2.25 billion in revenue each year. The business services provider earns $62.27 million in net income (profit) each year or $0.47 on an earnings per share basis.

The company employs 6,500 workers across the globe.

TrueBlue's mailing address is 1015 A STREET, TACOMA WA, 98402. The official website for the company is www.trueblue.com. The business services provider can be reached via phone at (253) 383-9101, via email at investorrelations@trueblueinc.com, or via fax at 877-733-0399.